Objectives: To describe the predictive factors for the isolation of fluoroquinolone-resistant or extendedspectrum b-lactamase (ESBL)-producing Escherichia coli and their impact on bacteraemia outcome.
Introduction
Escherichia coli is the most frequent Gram-negative microorganism causing bacteraemia worldwide and several studies have been focused on the prognostic factors of these bloodstream infections. 1 -7 Over the last decade, there has been a marked increase in infections caused by antibiotic-resistant E. coli that could have changed the outcome in patients with bacteraemia. Fluoroquinolone-resistant E. coli and, particularly, extendedspectrum b-lactamase (ESBL)-producing E. coli are of great concern due to their increased incidence and their frequent associated resistance to other groups of antimicrobial agents. 8 -10 This increasing resistance limits treatment options and may affect the prognosis of the E. coli infections. 11 -15 Promptness of adequate antibiotic therapy can influence the outcome of bloodstream infections. Growing resistance to antibiotics may lead to an increase in inappropriate empirical antimicrobial treatment of infections with a delay in the correct therapy.
This study was undertaken to describe the source, resistance rate to fluoroquinolone and b-lactam antibiotics and mortality of E. coli bacteraemia episodes reported during the 1991 -2007 period in a single institution and to identify the predictive factors for the isolation of fluoroquinolone-resistant or ESBLproducing strains.
Patients and methods

Setting and data collection
The setting was the Hospital Clínic in Barcelona, a 700 bed university tertiary centre that provides specialized and broad medical, surgical and intensive care for an urban population of 500 000 people. This hospital has followed a blood culture surveillance programme since 1990. Briefly, one infectious disease specialist and one microbiologist review the charts of patients with positive blood cultures and recommend antibiotic therapy, according to the clinical context and the results of the Gram stain, organism identification and susceptibilities. The patient is then followed until discharge or death. Data regarding the episode of bacteraemia are thus collected prospectively and entered in a database designed specifically for the blood culture surveillance programme.
Study design and inclusion criteria
The type of study was an analysis of cases of E. coli bacteraemia prospectively collected through the previously described blood culture surveillance programme from January 1991 to December 2007. The Ethics Committee of the hospital approved the study. Written informed consent was obtained from patients.
Microbiological methods
Between 1991 and 1997, blood samples were processed by the BACTEC NR-730 system (Becton-Dickinson Microbiology Systems) and maintained routinely for 7 days. Since 1998, we have used the BACTEC 9240 system (Becton-Dickinson Microbiology Systems), with an incubation period of 5 days. Isolates were identified by standard techniques. 19 Antimicrobial susceptibility testing was performed by a microdilution system (Microscan, Dade Behring, West Sacramento, CA, USA, or Sensititre, Trek Diagnostic Systems, East Grinstead, West Sussex, UK, or Phoenix System, Becton Dickinson, Franklin Lakes, NJ, USA). MICs observed with the three systems were interpreted using CLSI guidelines. 20 The recommendations advocated in the CLSI documents were also followed to detect the production of an ESBL. Microorganisms reported as intermediate were considered resistant.
Patient characteristics
The following data were obtained for all patients: age, sex, preexisting co-morbidities, prognosis of the underlying disease, prior antibiotic therapy, prior surgery (within the last month), current administration of 20 mg of corticosteroids every day, current administration of anti-neoplastic chemotherapy, source of bacteraemia, leucocyte count, origin of the infection (community-acquired or nosocomial, including last conventional hospitalization or outpatient visit), length of hospitalization before diagnosis of bacteraemia, ICU admission, need for mechanical ventilation, empirical and definitive antibiotic treatment, susceptibility to antibiotics of the microorganism isolated, presence of shock, and mortality.
Definition of terms
Significant bacteraemia was defined as one or more blood cultures positive for E. coli and clinically apparent signs and symptoms of sepsis (as described previously). 21 An episode of E. coli bacteraemia was thought to be nosocomial if it took place 72 h after admission, or if the patient had been hospitalized within 2 weeks before the current admission or had received long-term healthcare (healthcarerelated); otherwise, the bacteraemia was considered communityacquired. The source of infection was determined by a senior infectious disease specialist, who considered the patient's medical history, physical examination and the results of other microbiological tests and complementary imaging exploration. Definitions of the source of bacteraemia, such as pneumonia, urinary tract infection, surgical site infection or another, were as described previously. 22, 23 An intravenous catheter was considered to be the source of bacteraemia when, in the absence of any other clinically apparent focus, any of the following criteria was present: local inflammatory signs or suppuration at the insertion site; a positive culture of the catheter tip where the E. coli with the same susceptibility pattern as that isolated in peripheral blood was grown; at least 2 h difference in the time of growth between catheter and a venepuncture-drawn blood culture; and, finally, spontaneous resolution of sepsis within 24 h after catheter withdrawal without antibiotic treatment. 24, 25 When no focal infection could be demonstrated, the source was categorized as unknown.
Co-morbidity was defined as a disease or therapy that could predispose patients to infection, alter defence mechanisms or cause functional impairment, such as the following: diabetes; liver cirrhosis; renal failure; alcoholism (.100 g of alcohol every day); injecting drug users; active neoplastic disease; severe chronic obstructive pulmonary disease; severe cardiac disease with symptomatic heart failure; severe dementia; and administration of immunosuppressive drugs (20 mg of corticosteroids every day on a regular basis or anti-neoplastic chemotherapy). Prognosis of the underlying disease was classified, according to a modification of the criteria of McCabe and Jackson, as rapidly fatal (when death was expected within 3 months), ultimately fatal (when death was expected within a period of .3 months but ,5 years) and non-fatal (when life expectancy was 5 years). 26 Prior antibiotic therapy was defined as the use of any antimicrobial agent for 3 days during the month prior to the occurrence of the bacteraemic episode. Antibiotic treatment, either empirical or definitive (before or after the microbiological results and susceptibilities were known, respectively), was considered appropriate if at least one of the antibiotics involved had in vitro activity against the bacteria and the dose and route of administration were adequate. Shock was defined as a systolic pressure of ,90 mmHg that was unresponsive to fluid treatment or required vasoactive drug therapy. 21 Death was considered related to the bloodstream infection if it occurred before the resolution of symptoms or signs or within 7 days of the onset of bacteraemia, and if there was no other explanation; otherwise, death within 30 days of the onset of bacteraemia was considered unrelated to the episode.
Follow-up
Patients were observed from the diagnosis of bacteraemia until 30 days afterwards, until death in hospital or until discharge.
Statistical analysis
Statistical analyses were carried out using the program SPSS (version 14.0; SPSS, Chicago, IL, USA). Continuous variables are expressed as mean+SD or median (range) according to their homogeneity. Categorical variables were compared using the x 2 test or Fisher's exact test (when necessary). The quantitative variables were compared using the Student-Fisher t-test or ANOVA. Non-parametric tests were used when the application conditions were not applicable. Statistical significance was defined as a two-tailed P value ,0.05. Variables with P 0.2 in the univariate analysis were further analysed by using a stepwise non-conditional (logistic regression) multivariate analysis to find out the independent factors associated with mortality. For analysis purposes, we considered related and unrelated mortality (within 30 days of bloodstream infection) together.
Results
During the period of study, 4758 E. coli bacteraemia episodes out of 18 080 (26%) bloodstream infections were reported. E. coli isolation occurred in 40% of community-acquired and 14% of nosocomial bacteraemia episodes. Table 1 shows the epidemiological and clinical characteristics of episodes. There were 1399 (29%) cases of nosocomial acquisition. In 349 (7%) cases, the empirical therapy was inappropriate. One thousand and three hundred strains (27%) were resistant to fluoroquinolones and 211 cases (4%) were ESBL-producing strains. Mortality was noted in 440 cases (9%).
The more frequent sources of bacteraemia are reported in Table 2 . Pneumonia, intra-abdominal infection, skin and soft tissue infection and unknown focus were the bacteraemia sources with a higher mortality (37%, 26%, 18% and 15%, respectively). On the other hand, catheter-related bacteraemia, skin and soft tissue infection and unknown focus were the bacteraemia sources with a higher proportion of fluoroquinolone-resistant isolates (51%, 42% and 39%, respectively). The bacteraemia sources with a higher proportion of ESBL-producing strains isolated were skin HSCT, haematopoietic stem cell transplantation; SOT, solid-organ transplantation; FQ, fluoroquinolone; ESBL, extended-spectrum b-lactamase.
and soft tissue infection and catheter-related bacteraemia (13% and 11%, respectively). The chronological evolution of incidence and antibiotic susceptibility of E. coli isolates is shown in Table 3 . The fluoroquinolone resistance increased during the period of the study (13% in 1991 -95, 25% in 1996 -2000 and 35% in 2001 -07). There was also an increase in ESBL-producing strains during the 2001 -07 period (8% compared with 2% in the previous period). Mortality accounted for 10% during the last 12 years.
Risk factors for mortality
The independent risk factors for mortality are shown in Table 4 . The two main independent risk factors for mortality were shock at presentation (OR: 10.28, 95% CI: 7.80-13.56, P , 0.001), followed by inappropriate empirical therapy (OR: 4.83, 95% CI: 3.48-6.71, P , 0.001). The isolation of an antibiotic-resistant strain was not an independent risk factor for mortality. Inappropriate empirical therapy was significantly more frequent for infections caused by fluoroquinolone-resistant strains (n ¼ 203, 16%, P , 0.001) and ESBL-producing strains (n ¼ 110, 52%, P , 0.001) ( Table 5 ).
Risk factors for the isolation of an antibiotic-resistant strain
Independent risk factors associated with the isolation of a fluoroquinolone-resistant strain (Table 6) were: nosocomial origin (OR: 1.61, P , 0.001); urinary catheterization (OR: 2.44, (29) 440 (9) 1300 (27) 211 (4) FQ, fluoroquinolone; ESBL, extended-spectrum b-lactamase. a % of column. b % of row.
P , 0.001); and previous antibiotic therapy with a fluoroquinolone (OR: 7.41, P , 0.001). The independent risk factors associated with the isolation of an ESBL-producing strain (Table 7) were: nosocomial origin (OR: 1.68, P ¼ 0.03); urinary catheterization (OR: 1.88, P ¼ 0.001); and previous therapy with a b-lactam antibiotic (OR: 2.81, P , 0.001).
For data regarding univariate analysis for mortality, fluoroquinolone susceptibility and ESBL production, please see Tables  S1-S3 [available 
Discussion
E. coli is the main causal agent of community-acquired bacteraemia and the third most frequent pathogen causing nosocomial bloodstream infection, and its incidence remained stable during the study period. According to our data, the main source of E. coli bacteraemia was urinary tract infection (55%) followed by unknown focus and biliary infection (14% and 13%, respectively). Mortality was noted in 440 cases (9%) in our series, but it was higher in cases where pneumonia and intra-abdominal infection were the bacteraemia sources (37% and 26%, respectively). Similar to previously reported data, we observed a higher proportion of fluoroquinolone-resistant and ESBL-producing isolates in the last years of the study (2001-07, 35% and 8%, respectively). 27 Furthermore, the proportion of strains resistant to antibiotics was higher in bloodstream infections that were catheter-related (51% and 11%, respectively), skin and soft tissue infections (42% and 13%, respectively) and unknown focus (39% and 7%, respectively). In our series, the independent risk factors for mortality were: shock, co-morbidity (liver cirrhosis, chronic renal insufficiency, solid-organ cancer, neutropenia and simultaneous treatment with corticosteroids); the presence of pneumonia or intra-abdominal infection; and inappropriate empirical therapy. From these variables, empirical antibiotic therapy is the only one we could modify to decrease the mortality rate. When factors associated with inappropriate empirical treatment were studied, we found that they were more frequent in cases of antibiotic-resistant E. coli strains. Peralta et al. 18 reported similar results in their study with 663 episodes of E. coli bacteraemia, of which 525 (79%) cases were of nosocomial origin. 18 During the previous years of this decade, most investigations were performed regarding the clinical significance of infections caused by antibiotic-resistant E. coli strains. A number of studies found no significant association between ESBL production or fluoroquinolone resistance and crude mortality. 11 -12,28 In contrast, several other studies observed that patients with infection due to antibiotic-resistant bacilli tended to have poorer outcomes. 29 -31 Probably, inappropriate empirical treatment, which is more frequent in cases of antibiotic-resistant E. coli, is the main factor that determines mortality. This could explain the controversy that exits in the literature about the impact of infections caused by antibiotic-resistant isolates on outcome. 32 Therefore, it would be interesting to know the factors predictive of the isolation of an antibiotic-resistant E. coli with the objective of adequate empirical therapy. Numerous studies have assessed the variables associated with ESBL-producing enterobacteria colonization or infection. 27 According to our data, nosocomial acquisition and urinary catheterization were clinical predictive factors for an antibiotic-resistant isolation. Furthermore, previous antibiotic therapy with a fluoroquinolone or b-lactam was a predictive factor for the isolation of a fluoroquinolone-resistant or ESBL-producing E. coli strain, respectively.
There are several potential limitations to our study. First, we have reported the results of a retrospective analysis of a database prospectively collected for more than 15 years. Consequently, it is very difficult to review charts and in several cases there were several lost values. Second, we considered related and unrelated mortality together. This is an analysis option used almost always in bloodstream infection outcome studies, but the factors associated with mortality in the first week after the bacteraemia diagnosis could be different from those associated with a fatal outcome during the 30 posterior days. And third, MIC values were not available in the database. We reported susceptibility as a categorical variable, and this was a limitation to study the relation between MIC value, empirical or definitive treatment and outcome. Finally, in hospital settings similar to ours, when E. coli bacteraemia is suspected to be associated with severe sepsis or septic shock, a high-risk mortality source (peritonitis or pneumonia) with risk factors for a fluoroquinolone-resistant or ESBL-producing isolation or focus with a higher proportion of resistant strains (catheter-related bacteraemia, skin and soft tissue infection or unknown focus), the initial empirical treatment should include an antibiotic with activity against cephalosporin-resistant isolates such as a carbapenem or tigecycline.
